Daily CSR

Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy

2026-04-16T16:34:00+02:00

Intensity Therapeutics, Inc., a late-stage biotechnology firm, focuses on discovering and developing proprietary cancer treatments using its non-covalent drug-conjugation technology. This approach is designed to destroy tumors while enhancing the immune system’s ability to recognize cancer. The company has been named a winner at the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and its leading drug candidate, INT230-6.

The company earned a Platinum award in the Innovator in Biotech Solutions category. INT230-6, Intensity’s primary investigational therapy, is intended for direct injection into tumors. It combines two well-established anticancer drugs—cisplatin and vinblastine sulfate—with a diffusion and cell penetration enhancer known as SHAO. This component enables the drugs to spread more effectively throughout tumors and enter cancer cells more efficiently. INT230-6 is currently being developed alongside standard treatment approaches to enhance long-term responses across a range of solid tumor types.

According to co-founder and CEO Lewis H. Bender, the Pinnacle Award recognition highlights the company’s dedication to transforming cancer treatment. He noted that INT230-6 introduces a novel mechanism for inducing cancer cell death, with the potential to shift cancer from an acute, often fatal condition to a manageable chronic disease, even in cases that do not respond to immunotherapy.

The Pinnacle Awards is a respected annual program that honors excellence across multiple industries. It recognizes organizations, products, and individuals that demonstrate significant innovation, creativity, and impact. Each year, candidates are assessed by a panel of industry experts, media professionals, and consultants to ensure that only the most deserving recipients are selected.

Viva Biotech Expands Integrated Drug Discovery and Innovation in Europe

2026-04-07T12:23:00+02:00

Marking more than 15 years of partnership with Europe’s drug discovery community, Viva Biotech is reinforcing its dedication to the region through operational consistency, steady growth, and scalable collaboration. As the European biopharmaceutical sector undergoes major structural transformation, the importance of a dependable, long-term research partner has become increasingly critical to sustaining progress in key innovation initiatives.

Ensuring Stability in a Shifting Environment
Across Europe, clients see Viva Biotech as more than a service provider—they regard it as a trusted partner and an extension of their own teams. With a strong UK presence and specialized regional teams, the company delivers responsive, well-coordinated support throughout the complexities of the drug discovery process.

Consistent Foundation: Despite broader industry disruption, Viva Biotech has maintained stability, growing alongside its European partners for over 15 years.
Local Expertise with Global Reach: Its UK base, combined with dedicated business development and project management teams, ensures hands-on support while seamlessly integrating global capabilities across cross-border projects.
Trust-Driven Partnerships: In an industry where continuity is crucial, the company focuses on building long-term relationships through reliable delivery of scientific milestones year after year.

Driving Innovation Through Expanded Integrated Capabilities
To support partners in moving from early discovery to candidate selection with greater confidence, Viva Biotech continues to expand its platforms—positioning itself as a fully integrated partner across discovery, development, and manufacturing.

Comprehensive Scientific Integration: By combining Structure-Based Drug Discovery (SBDD), cryo-EM, and medicinal chemistry into a unified workflow, the company enables seamless progression from early discovery to lead optimization and candidate selection. Its expertise spans both traditional small molecules and emerging modalities such as peptides and proximity-inducing compounds.
AI-Enhanced Discovery: Advanced AI-driven design tools are embedded within workflows, already contributing to nearly 200 projects by enabling faster, data-informed decision-making.
Deep Structural Expertise: With experience covering more than 98,000 protein structures, over 200 cryo-EM structures, and 200+ membrane protein targets, partners benefit from strong technical insight.
End-to-End Development Support: Extending into CMC and CDMO services, the platform bridges discovery and manufacturing, supporting projects through commercialization and process performance qualification. To date, this integrated model has advanced 295 drug programs at the CMC stage.

Shaping the Future of European Drug Discovery
The past 15 years in Europe have been marked by scientific excellence and strong, trust-based collaborations. Viva Biotech looks forward to continuing this journey, partnering with the next generation of innovators to drive future breakthroughs in drug discovery.

Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty

2026-01-15T05:04:00+01:00

Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States.

During its presentation at Biotech Showcase 2026, the company outlined a forward-looking antiviral approach centered on Xafty, a broad-spectrum therapeutic designed to combat multiple viruses. Marking a decisive shift in focus, the company stated that preparations in Vietnam have been finalized and that efforts are now moving to the U.S. market.

A Long-Awaited Broad-Spectrum Antiviral
A major focus of the announcement was the clinical framework developed in partnership with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD).

Dr. Smith, an internationally recognized infectious disease specialist who previously headed the U.S. government’s ACTIV-2 COVID-19 clinical trials, described the current public health landscape in the U.S. as a “tripledemic” driven by influenza, RSV, and emerging COVID-19 strains—conditions that currently lack a single, comprehensive treatment solution.

Commenting on the trial design, Dr. Smith explained that Xafty offers the potential to address several viral infections simultaneously. He noted that the innovative “basket trial” model enables efficient evaluation across multiple viruses and represents a practical response to the ongoing multi-virus challenge. Emphasizing urgency, he stressed the importance of accelerating clinical progress to bring new treatment options to patients as quickly as possible.

“One Drug, Two Tracks”: A Global Strategy
Hyundai Bioscience also introduced its “One Drug, Two Tracks” development model, which deploys Xafty across two distinct clinical pathways:

Dengue fever trials in Vietnam
Upper respiratory viral infection trials in the United States

By advancing the same drug in different viral settings, the company aims to demonstrate Xafty’s wide-ranging antiviral capability, spanning both mosquito-transmitted and respiratory infections. The strategy mirrors the versatility of modern antibiotics that are effective against multiple bacterial strains.

Jason Kim, CEO of Hyundai Bioscience USA, noted that discussions at the showcase confirmed strong alignment between the company’s clinical strategy and unmet needs within the U.S. healthcare system. He added that all preparations are in place and that the company is ready to promptly file its Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Looking Ahead: A New Era in Antiviral Treatment
The presentation concluded with a forward-looking vision for global health. Dr. Smith observed that antiviral development has historically been reactive, focused on chasing evolving variants. He expressed confidence that a preventive, broad-spectrum approach could redefine the field, positioning this clinical trial as a potential milestone in the development of antivirals capable of targeting multiple viruses with a single therapy.